LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

Search

Ovid therapeutics Inc

Atvērts

SektorsVeselības aprūpe

1.22 2.52

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.13

Max

1.29

Galvenie mērījumi

By Trading Economics

Ienākumi

5.6M

-4.7M

Pārdošana

6.1M

6.3M

Peļņas marža

-74.681

Darbinieki

23

EBITDA

7.3M

-5.1M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+139.34% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 10. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

42M

81M

Iepriekšējā atvēršanas cena

-1.3

Iepriekšējā slēgšanas cena

1.22

Ziņu noskaņojums

By Acuity

43%

57%

151 / 372 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 27. aug. 22:51 UTC

Peļņas

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

2025. g. 27. aug. 23:57 UTC

Peļņas

Trip.com Group 1H Rev $4.01B

2025. g. 27. aug. 23:57 UTC

Peļņas

Trip.com Group 1H Adj EPS $1.84

2025. g. 27. aug. 23:57 UTC

Peļņas

Trip.com Group 1H EPS $1.82

2025. g. 27. aug. 23:50 UTC

Tirgus saruna

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

2025. g. 27. aug. 23:39 UTC

Peļņas

Correction to Nvidia Earnings Article -- WSJ

2025. g. 27. aug. 22:59 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 27. aug. 22:59 UTC

Tirgus saruna

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

2025. g. 27. aug. 22:58 UTC

Peļņas

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

2025. g. 27. aug. 22:57 UTC

Peļņas

South32 FY Free Cash Flow $192 Million

2025. g. 27. aug. 22:56 UTC

Peļņas

South32 FY Total Capital Expenditure $1.35 Billion

2025. g. 27. aug. 22:56 UTC

Peļņas

South32 FY Capital Expenditure $963 Million, Excluding EAIs

2025. g. 27. aug. 22:55 UTC

Peļņas

South32 Net Cash $123 Million at June 30

2025. g. 27. aug. 22:54 UTC

Peļņas

South32: Focused on Maintaining Strong Operating Momentum

2025. g. 27. aug. 22:53 UTC

Peļņas

South32: $144 Million Remains to be Returned to Shareholders Under Program

2025. g. 27. aug. 22:53 UTC

Peļņas

South32 Extends Capital Management Program for 12 Months

2025. g. 27. aug. 22:52 UTC

Peļņas

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

2025. g. 27. aug. 22:51 UTC

Peļņas

South32 FY Revenue $5.78 Billion, Up 17% On-Year

2025. g. 27. aug. 22:51 UTC

Peļņas

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

2025. g. 27. aug. 22:50 UTC

Peļņas

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

2025. g. 27. aug. 22:50 UTC

Peļņas

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

2025. g. 27. aug. 22:45 UTC

Peļņas

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

2025. g. 27. aug. 22:44 UTC

Peļņas

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

2025. g. 27. aug. 22:44 UTC

Peļņas

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

2025. g. 27. aug. 22:43 UTC

Peļņas

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

2025. g. 27. aug. 22:43 UTC

Peļņas

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

2025. g. 27. aug. 22:42 UTC

Peļņas

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

2025. g. 27. aug. 22:42 UTC

Peļņas

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

2025. g. 27. aug. 22:40 UTC

Peļņas

Sandfire Resources Net Debt $123 Million at June 30

2025. g. 27. aug. 22:40 UTC

Peļņas

Sandfire Resources FY Underlying Ebitda $527.7 Million

Salīdzinājums

Cenas izmaiņa

Ovid therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

139.34% augšup

Prognoze 12 mēnešiem

Vidējais 2.92 USD  139.34%

Augstākais 5.5 USD

Zemākais 0.5 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ovid therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

7

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

0.275 / 0.33Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

151 / 372 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.